Evidence map›Paper›PMID 29692183›Full record

Trial reportCell transplantation2018

Effects of Moxibustion on the Levels of Insulin-Like Growth Factor 1: A Pilot Study.

Jaung-Geng Lin, Shinn-Zong Lin, Lih-Hwa Lin, Chun-Chang Wu, Wan-Ting Tsai, Horng-Jyh Harn, Li-Hui Su, Wen-Yu Ho, Che-Jui Hsieh, Tsung-Jung Ho

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Jaung-Geng Lin1 School of Chinese Medicine, China Medical University, Shenyang Shi, Taichung, Taiwan.
Shinn-Zong Lin2 Bioinnovation Center, Tzu Chi Foundation, Department of Neurosurgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien, Taiwan.
Lih-Hwa Lin3 Division of Chinese Medicine, An Nan Hospital, China Medical University, Liaoning Sheng, Tainan, Taiwan.
Chun-Chang Wu5 Division of Chinese Medicine, China Medical University Beigang Hospital, Yunlin County, Taiwan.
Wan-Ting Tsai5 Division of Chinese Medicine, China Medical University Beigang Hospital, Yunlin County, Taiwan.
Horng-Jyh Harn6 Bioinnovation Center, Tzu Chi Foundation, Department of Pathology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien, Taiwan.
Li-Hui Su7 Department of Nursing, China Medical University Beigang Hospital, Yunlin County, Taiwan.
Wen-Yu Ho8 Department of Laboratory Medicine, China Medical University Beigang Hospital, Yunlin County, Taiwan.
Che-Jui Hsieh1 School of Chinese Medicine, China Medical University, Shenyang Shi, Taichung, Taiwan.
Tsung-Jung Ho1 School of Chinese Medicine, China Medical University, Shenyang Shi, Taichung, Taiwan.
China Medical University · TWChina Medical University Beigang Hospital · TWAn-Nan Hospital · TWTzu Chi Foundation · TWTzu Chi University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Moxibustion () is a traditional Chinese medicine therapy performed using Artemisia argyii. Zusanli (, ST36) is an acupoint in the stomach meridian, long associated in ancient Chinese medical practices with the extension of life span when moxibustion is applied to it. The aim of this study was to investigate changes in insulin-like growth factor 1 (IGF-1) levels after application of moxibustion to ST36. Four healthy men and women participated in this 28-day trial and were randomly divided into 2 groups. Group A received moxibustion treatment from days 1 to 14, while group B received moxibustion treatment from days 15 to 28. Blood samples were taken 5 times during this study to measure serum IGF-1 (s-IGF-1) levels. The s-IGF-1 levels increased in both groups after 7 and 14 d of moxibustion therapy (group A: 11.02% [7 d] and 29.65% [14 d]; group B: 169.12% [7 d] and 274.85% [14 d]). After moxibustion therapy had been completed (day 14), s-IGF-1 levels continued to increase in group A (increases on day 21 and day 28 were 53.19% and 61.45%, respectively). There were no adverse events in either group. The s-IGF-1 levels were significantly raised in both groups after 7 and 14 d of moxibustion therapy. Moreover, once therapy had been completed, s-IGF-1 levels continued to increase in group A up to 14 d after the treatment.

Indexed as

MoxibustionAdultFemaleHumansInsulin-Like Growth Factor IMalePilot ProjectsInsulin-Like Growth Factor Iinsulin-like growth factor 1moxibustionST36 acupointZusanli acupoint

Identifiers

PMID29692183
PMCPMC6038048
OpenAlexW2799957166

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.